SC
VRTX icon

Seldon Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Seldon Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-120
Closed -$34.7K – 244
2022
Q4 		$34.7K Hold
120
– – 0.03% 164
2022
Q3 		$35K Hold
120
– – 0.03% 169
2022
Q2 		$34K Hold
120
– – 0.02% 182
2022
Q1 		$31K Hold
120
– – 0.02% 199
2021
Q4 		$26K Buy
+120
New +$23.3K 0.02% 220

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Seldon Capital's VRTX Position: Q1 2023 in Review

Seldon Capital sold out of Vertex Pharmaceuticals (VRTX) in Q1 2023, closing a stake of 120 shares — an estimated $34.7K sold.

Seldon Capital first reported a position in VRTX in Q4 2021 and held it in 5 quarters. The position peaked at $35K in Q3 2022. 1,207 funds tracked by Wall St. Rank hold VRTX as of Q1 2023.

  • Seldon Capital reported no remaining Vertex Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Seldon Capital sold 120 Vertex Pharmaceuticals shares in Q1 2023, an estimated $34.7K.
  • Seldon Capital first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 5 quarters.
  • Seldon Capital's Vertex Pharmaceuticals position peaked at $35K in Q3 2022.
  • 1,207 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2023.

Based on Seldon Capital's 13F filing for Q1 2023, filed 12 May 2023.